BioVersys AG (FRA:W33) Moat Score: 0/10 (As of Jul. 06, 2026)


FRA:W33 BioVersys AG FRA:W33
7 GF Score
Price €28.00
View Full Analysis

What is BioVersys AG Moat Score?

BioVersys AG has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

BioVersys AG has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioVersys AG might have No Moat - No discernible moat.

BioVersys AG  (FRA:W33) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioVersys AG Moat Score Related Terms

FRA:W33
7GF Score
BioVersys AG FRA:W33
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score

Get the complete analysis for FRA:W33

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.00
Price